Nomegestrol derivatives-based subcutaneous implants
CA 2122827 A1 · Owner: Lanquetin, Michel · Inventors: Coutinho, Elsimar; Lanquetin, Michel; Thomas, Jean-Louis
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to the field of therapeutical chemistry and more particularly to pharmacotechny. Specially the present invention relates to new compositions adapted to local administration and more precisely to forms intended to be placed in the subcutaneous tissues and commonly called implants. Said implants are of various natures (hydrophobic hydrophilic, biodegradable) and of various types (reservoir matrix). Said implants incorporate an efficient dose of a derivative of 3,20-dioxo 6-methyl 17(alpha)-acetoxy 19-nor pregna 4,6-diene optionally substituted in the 3 and/or 17(alpha) position associated or mixed with a biologically acceptable inert excipient. The implants thus …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 17, 1993. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 17, 2013.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 17, 2015.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.